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Abstract
Background: N-butylidenephthalide (BP) exhibits antitumor effect in a variety of cancer cell lines. The objective of this study
was to obtain additional insights into the mechanisms involved in BP induced cell death in human prostate cancer cells.
Methods/Principal Findings: Two human prostate cancer cell lines, PC-3 and LNCaP, were treated with BP, and
subsequently evaluated for their viability and cell cycle profiles. BP caused cell cycle arrest and cell death in both cell lines.
The G0/G1 phase arrest was correlated with increase levels of CDK inhibitors (p16, p21 and p27) and decrease of the
checkpoint proteins. To determine the mechanisms of BP-induced growth arrest and cell death in prostate cancer cell lines,
we performed a microarray study to identify alterations in gene expression induced by BP in the LNCaP cells. Several BP-
induced genes, including the GADD153/CHOP, an endoplasmic reticulum stress (ER stress)-regulated gene, were identified.
BP-induced ER stress was evidenced by increased expression of the downstream molecules GRP78/BiP, IRE1-a and
GADD153/CHOP in both cell lines. Blockage of IRE1-a or GADD153/CHOP expression by siRNA significantly reduced BP-
induced cell death in LNCaP cells. Furthermore, blockage of JNK1/2 signaling by JNK siRNA resulted in decreased expression
of IRE1-a and GADD153/CHOP genes, implicating that BP-induced ER stress may be elicited via JNK1/2 signaling in prostate
cancer cells. BP also suppressed LNCaP xenograft tumor growth in NOD-SCID mice. It caused 68% reduction in tumor
volume after 18 days of treatment.
Conclusions: Our results suggest that BP can cause G0/G1 phase arrest in prostate cancer cells and its cytotoxicity is
mediated by ER stress induction. Thus, BP may serve as an anticancer agent by inducing ER stress in prostate cancer.
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Introduction
Prostate cancer is the most common malignancy in American men
and the second leading cause of deaths from cancer [1]. The
treatment options for patients include surgery, radiation therapy,
hormonal therapy, chemotherapy, and combinations of someof these
treatments. One of the most common chemotherapy agent used for
the treatment of prostate cancer are the taxanes, such as the first
generation drug paclitaxel (Taxol, a trademark of Bristol-Myers
Squibb) [2,3]. Increased concentrations of cytotoxic drugs and higher
dosages of irradiation fail to improve the response to therapy and it
leads to apoptosis resistance in prostate cancer cells. Therefore, newly
developed anticancer agents that are nontoxic and highly effective in
inducing apoptosis preferentially in tumor cells are valuable.
Recently, non-traditional treatments using herbs and dietary
supplements have been considered as alternative medicines for
cancer therapy. Angelica sinensis (also called danggui in Chinese) is
one of the most commonly used traditional herbs in China. It is
recommended as a tonic, hemopoetic, spasmolytic, and analgesic
drug in clinical practice [4]. In our previous study, n-butylide-
nephthalide (BP), a compound isolated from Angelica sinensis
chloroform extract, exhibits growth inhibitory activity on various
human cancer cell lines, including brain, lung and liver cancer
cells. BP caused growth arrest and apoptosis in these tumor cells in
vitro and in vivo [5–7]. These findings indicate that BP is a
promising new anticancer compound with a potential for clinical
application. However, the effect of BP on prostate cancer cells has
not been addressed.
Protein folding in the endoplasmic reticulum (ER) is impaired
under various physical and pathological conditions, termed ER
stress. A specific signaling pathway, the unfolded protein response
(UPR), has been demonstrated in cell to overcome ER stress [8].
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widely recognized as a marker for ER stress and the onset of UPR.
The UPR signals through three distinct stress sensors located at
the ER membrane: protein kinase RNA-like ER kinase (PERK),
inositol-requiring protein-1 a (IRE1-a) and activating transcrip-
tion factor-6 (ATF6) [9]. Among them, IRE1-mediated activation
of Jun N-terminal kinase (JNK) contributes to cell death by
phosphorylating and inactivating the anti-apoptotic regulator
BCL-2 [10]. The transcription factor CCAAT/enhancer-binding
protein (C/EBP)-homologous protein (CHOP; also known as
DDIT3/GADD153) operates at the convergence of the PERK,
IRE1-a and ATF6 pathways [11,12]. Overexpression of CHOP
plays an important role in apoptosis [13] through dephosphory-
lates the proapoptotic BH3-only protein Bad and down-regulates
Bcl-2 expression [14].
This present study sought: 1) to determine the anti-proliferative
effect of BP in vitro and in vivo, 2) to assay the effects of BP on cell
cycle progression and apoptosis, 3) to investigate ER stress as a
potential molecular target of BP, and 4) to establish whether
MAPK/ER stress signaling is involved in BP-mediated apoptosis
in prostate cancer. The effects of BP in prostate cancer were
evaluated in vitro in LNCaP and PC-3 cell lines. LNCaP-NOD-
SCID mice xenograft experiment was used to assess the anticancer
effect of BP in vivo.
Results
BP inhibited proliferation and induced morphology
changes in human prostate cancer cells
BP has a strong anti-proliferative effect on GBM cells and
caused G0/G1 phase arrest and apoptosis in a time- and
concentration-dependent manner. To determine the cytotoxicity
effect of BP on prostate cancer cells, three human prostate cancer
cell lines were treated with increasing concentration of BP for 24
and 48 h, and were evaluated by the MTT assay. As shown in
Fig. 1A and B, BP significantly decreased the viability of DU-145,
PC-3 and LNCaP cells in a dose and time-dependent manner.
Treatment of LNCaP and PC-3 cells with 75 mg/ml BP for 48 h
resulted in 24.48% and 45.88% cell survival, respectively (Fig. 1B).
Based on these data, we used 70 mg/ml BP for subsequent studies.
To further investigate the cytotoxicity effect of BP on prostate
cancer cells, LNCaP (androgen-dependent) and PC-3 (androgen-
independent) cells were selected for further investigation. BP-
treated LNCaP and PC-3 cells showed obvious cell shrinkage and
rounding up, features typical of cells undergoing apoptosis (Fig. 1D
and F).
BP induced cell cycle arrest at G0/G1 phase and changed
the expression levels of G0/G1 regulatory proteins
In order to elucidate its mode of action, we examined the effects
of BP on cell cycle progression. Flow cytometry analysis showed
that BP treatment resulted in the accumulation of cells in G0/G1
phase in a time-dependent manner (Fig. 2A and B). Quantification
of proliferating untreated cells showed that 67.95% of cells were in
the G0/G1 phase, 24.96% of cells were in the S phase, and 7.73%
of cells were in the G2/M phase of cell cycle 12 h after plating in
LNCaP cells; 62.71% of cells were in the G0/G1 phase, 17.78% of
cells were in the S phase, and 19.50% of cells were in the G2/M
phase of cell cycle 12 h after plating in PC-3 cells. Treatment of
cells with 70 mg/ml BP for 12 h increased the percentage of cells
in the G0/G1 phase to 81.94% and reduced the percentage of the
cells in the S and G2/M phases to 10.6 and 8%, respectively, in
LNCaP cells. In PC-3 cells treated with 70 mg/ml BP for 12 h, the
percentage of cells in the G0/G1 phase increased to 69.94%, and
the cells in the S and G2/M phases decreased to 18.11 and
11.97%, respectively.
To determine the molecular mechanisms underlying the G0/
G1 cell cycle arrest in prostate cancer cells induced by BP, we
examined the expression of certain G0/G1 regulatory proteins in
LNCaP and PC-3 cells treated with 70 mg/ml BP. We first
examined the level of cyclin D1, the main cyclin controlling the
Figure 1. Effects of BP on the viability and morphological
changes of human prostate cancer cells. DU-145 (&), PC-3 (&),
LNCaP (%) cells were treated with increasing concentration of BP (25 to
100 mg/ml) for 24 (A) and 48 h (B) and analyzed with MTT assay. LNCaP
and PC-3 cells were treated with 0.2% DMSO (C and E, respectively) or
70 mg/ml BP (D and F, respectively) for 24 h, were shown.
doi:10.1371/journal.pone.0033742.g001
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in (A) LNCaP and (B) PC-3 cells. Cells were seeded at 8610
5 (LNCaP) and 6610
5 (PC-3) per 6-cm plate in triplicates and treated with 70 mg/ml BP for
12–24 h. Data are presented as means 6 S.D. from three different experiments. *, P,0.05; **, P,0.01. Western blot analysis of cyclin D1, CDK2, p16,
p21, p27 and phospho-Rb (Ser807/811) was performed in LNCaP cells (C) and PC-3 cells (D). b-actin was used as an internal control. Western blot
analysis of phospho-Akt (Ser473), Akt, phospho-GSK-3b (Ser9) and GSK-3b was performed in LNCaP cells (E) and PC-3 cells (F). b-actin was used as an
internal control.
doi:10.1371/journal.pone.0033742.g002
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D1 protein level (Fig. 2C and D). Upregulation of G0/G1 cell
cycle regulatory proteins such as p16, p21, p27, and downregu-
lation of CDK2 were also observed in a time-dependent manner
(Fig. 2C and D).We also observed a rapid reduction of Rb
phosphorylation level (Fig. 2C and D) indicating the compromised
activation of the CDK4/6.
It has been established that cyclin D1 phosphorylation is
mediated by the Akt-GSK-3b pathway. Activated Akt phosphor-
ylates and inhibits GSK-3b function, leading to the de-phosphor-
ylation and stabilization of cyclin D1. Therefore, we examined
whether the Akt-GSK-3b-Cyclin D1 pathway was involved in BP-
induced degradation of cyclin D1 in prostate cancer cells. Western
blot analysis showed that BP rapidly and markedly suppressed Akt
phosphorylation, as early as 10 min (Fig. 2E and F). Consistent
with the inhibition of Akt activity, reduced phosphorylation of
Ser9 in GSK-3b, a target of Akt kinase, was also noted (Fig. 2E
and F), suggesting that BP promotes cyclin D1 phosphorylation via
suppression of Akt and activation of GSK-3b. These data suggest
that BP suppresses Akt-GSK-3b pathway in prostate cancer cells
and causes G0/G1 growth arrest by affecting the expression of
G0/G1 regulatory proteins.
BP induced apoptosis in LNCaP and PC-3 cells
To evaluate the role of apoptosis in BP-induced cell death,
western blotting and TUNEL staining were performed. Activation
of caspases are crucial mechanisms for induction of apoptosis.
Caspase 28 and 23 were key protease associated with death
receptor mediated-apoptosis and their involvement in BP-induced
apoptosis was investigated in both LNCaP and PC-3 cells. BP-
induced caspase 28 and 23 cleavages increased dose-dependently
in both LNCaP and PC-3 cells (Fig. 3A and B). The pro-apoptotic
Bcl-2 family members, Bax, also increased after BP treatment
which have important link between IRE1 and ER-stress-induced
apoptosis. TUNEL staining at 48 h after 70 mg/ml BP treatment
also revealed increased number of apoptotic cells in both LNCaP
and PC-3 cells (Fig. 3D and F, respectively).
Gene expression analysis by cDNA microarray in BP-
treated LNCaP cells
To obtain insight into the mechanism of BP-induced growth
inhibition and cell death, we used oligodeoxynucleotide-based
microarray to identify BP-mediated gene expression. LNCaP cells
were treated with 70 mg/ml BP for 3 and 24 h, and RNA was
extracted and used in microarray analysis. Genes including
GADD153/CHOP were identified to be up-regulated in a time-
dependent manner (Table 1). We validated the up-regulation of
GADD153/CHOP genes by western blot. BP elicited an increased
expression of GADD153/CHOP protein in both LNCaP and PC-
3 cells (Fig. 4A and B). Up-regulation of GADD153/CHOP has
been defined as ER stress-response, which in turn triggers signals
to induce apoptosis. We thus investigated the role of ER stress in
BP-induced cell death in prostate cancer cells.
BP induced ER stress in LNCaP and PC-3 cells
To delineate the induction of ER stress by BP in prostate cancer
cells, we investigated the induction of UPR related genes after BP
treatment in LNCaP and PC-3 cells (Fig. 4A and B, respectively).
Expression of BiP increased after BP treatment, but no differences
were found in calnexin and PDI expressions (Fig. 4A and B). Up-
regulation of ER stress transducer IRE1-a was observed but not
ATF6 and p-eIF-2a. BP induced IRE1-a expression was evident
from 3 h (1.16 folds) and increased till 48 h (2.47 folds) in LNCaP
cells. The levels of Fas increased after BP treatment in both
LNCaP and PC-3 cells and were consistent with the microarray
finding in LNCaP cells. In addition, expressions of BiP, IRE1-a
and GADD153 increased dose dependently in both LNCaP and
PC-3 cells (Fig. 4C and D). The GADD153 transcriptional target,
ER oxidase 1 like a (ERO1-La) also increased in a dose-dependent
manner after BP treatment (Fig. 4C and D).
BP-induced nuclear translocation of GADD153/CHOP in
LNCaP and PC-3 cells
To study the involvement of GADD153/CHOP in BP
treatment, we first investigated whether BP promoted the
translocation of GADD153/CHOP protein to the nucleus.
GADD153/CHOP nuclear translocation represents the carrying
of stress signal into the nucleus and therefore a functional
activation. At 12 h after 70 mg/ml BP treatment, GADD153/
CHOP was apparently more abundant in the nucleus of BP-
treated LNCaP and PC-3 cells than in that of controls (Fig. 5A and
B).
The role of ER stress in BP-mediated anti-proliferation
We further used a siRNA approach to determine the role of
GADD153 in the anticancer potential of BP in prostate cancer.
LNCaP cells were transfected with siRNAs for GADD153 and
IRE1-a, respectively, with or without post treatment of 70 mg/ml
BP for 48 h. Western blot analysis demonstrated that transfection
of si-GADD153/CHOP resulted in a suppression of GADD153/
CHOP expression induced by BP in LNCaP cells, as compared
with cells transfected with control scrambled siRNA (Fig. 6A). Cell
death induced by BP treatment was rescued by 21.18% in cells
transfected with GADD153/CHOP siRNA as compared to
scrambled siRNA-transfected cells (Fig. 6B). Since GADD153/
CHOP gene promoter contains binding sites for all of the major
inducers of the UPR, and only IRE1-a was induced after BP
treatment (Fig. 4), we further characterized the role of IRE1-a in
BP-induced cell growth arrest and cell death. We silenced IRE1-a
expression by si-IRE1-a transfection prior to 70 mg/ml BP
treatment. As shown in Fig. 6C, IRE1-a siRNA significantly
blocked IRE1-a protein expression induced by BP treatment in a
dose dependent manner. In addition, GADD153/CHOP was also
suppressed by IRE1-a siRNA transfection. MTT assay showed
that 11.67 and 20.8% of cell death was inhibited by 20 and 50 nM
IRE1-a siRNA transfection after exposure of cells to 70 mg/ml BP,
respectively (Fig. 6D). Taken together, these results indicated that
BP-induced cell death may be involved, at least in part, through
the induction of ER stress and the up-regulation of IRE1-a and
GADD153/CHOP proteins expression.
The role of MAPK on BP-induced ER stress and cell death
Activation of MAPKs has been implicated in the regulation of
ER-stress induced cell death. We investigated the effect of BP on
MAPK activation. Exposure of LNCaP and PC-3 cells to 70 mg/
ml BP resulted in phosphorylation of JNK 1/2 and ERK 1/2, but
not p38 MAPK (Fig. 7A and B). The ERK 1/2 phosphorylation
after BP treatment occurred at 10 min and down-regulation
occurred at 30 min. On the contrary, the phosphorylation of JNK
1/2 sustained at 10 to 180 min. To further characterize the role of
JNK 1/2 in BP treatment, we silenced JNK 1/2 expression by
specific siRNA transfection. As shown in Fig. 7C, JNK 1/2
expression and phosphorylation after BP treatment reduced by si-
JNK transfection. In addition, the BP-induced expression of IRE1-
a and GADD153 also reduced by si-JNK transfection. BP-induced
cell death was rescued by si-JNK transfection, as compared to
n-butylidenephthalide Induces ER Stress in PCa
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20.95%, Fig. 7D). These findings suggest that JNK activation is
involved in BP-induced cell death and participates in IRE1-a and
GADD153 activation.
BP inhibits growth of cancer cells in LNCaP–NOD-SCID
xenograft
To evaluate the antitumor activity of BP in vivo, human prostate
cancer xenograft were established by subcutaneous injection of
5610
5 LNCaP cells into the dorsal subcutaneous tissue of NOD-
SCID mice. As shown in Fig. 8A, the relative tumor volume in
mice treated with 500 mg/kg BP was significantly 68% lower than
the vehicle-treated control mice on day 18. Tumor weight was
significantly decreased 56% in the BP-treated group as compared
to the control group on day 18 (Fig. 8B). The tumors in control
animals were graded as Gleason 5B since no glandular tissue was
found (Fig. 8C). In BP-treated animals, irregular fused glands were
observed and were staged Gleason 4A (Fig. 8D). Thus, the degrees
of tumor differentiation of BP-treated group were better than the
control group. Besides, up-regulation of GADD153/CHOP in the
BP-treatment tumor was observed by immunohistochemistry
staining (Fig. 8E and F) and western blot analysis (Fig. 8G),
respectively. Caspase-3 activation was also observed in BP-
treatment tumor (Fig. 8G). There were no significant differences
of body weight in both control and BP-treated groups. These
results indicated that BP-induced prostate cancer cell death was
correlated with ER stress in vivo.
Discussion
Currently some promising naturally-occuring dietary therapeu-
tic compounds include resveratrol, curcumin, genistein, diallyl
sulfide and other substances which have in common ability to
induce apoptosis of cancer cells have been exploited [15]. In our
previous studies, we demonstrated that BP act strongly against
glioblastoma multiforme (GBM) brain tumors and hepatocellular
carcinoma (HCC) tumors in vitro and in vivo [5,6,16]. However, the
effects of BP on human prostate cancer cells have not been
determined. Results from this study showed that BP is cytotoxic for
the three different prostate cancer cell lines. Because both of the
androgen-dependent and -independent prostate cancer cells
Figure 3. BP induces apoptosis in prostate cancer cells. Western blot analysis of active caspase 8, active caspase 3 and bax was performed in
LNCaP cells (A) and PC-3 cells (B). b-actin was used as an internal control. LNCaP cells and PC-3 cells were incubated in the absence (C and E,
respectively) or presence (D and F, respectively) of 70 mg/ml BP for 48 h and then subjected to TUNEL assay.
doi:10.1371/journal.pone.0033742.g003
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androgen pathway was ignored in this study.
The loss of cell cycle regulation is the hallmark of cancer. To
explore the mechanisms accounted for the effect of BP on prostate
cancer cells, cell cycles were monitored. BP-induced cell cycle
arrest was evidenced by up-regulation of p16, p21 and p27, and
down-regulation of CDK2 and cyclin D1. The p16, p21 and p27
proteins are cdk inhibitors that negatively regulate cdk or cyclin/
cdk complex [17]. The p16 protein, member of the INK4 family,
binds to cdk4/6 to block kinase activity at the mid-G1 phase [18].
The p21 (cip1) and p27 (kip1) proteins bind to the cyclin/cdk
complex, resulting in the inhibition of G1 to S phase transition via
the abrogation of Rb phosphorylation by the cyclin/cdk complex
[19]. Thus, the decrease of phosphorylated Rb should be due to a
BP-triggered expression of the cdk inhibitors, which in turn
decrease the activity of the cyclin/cdk complex. Frequent
activation of Akt signaling pathway has been reported in many
human cancers [20,21], and GSK-3b has been identified as one of
the Akt’s molecular targets. Akt inactivates GSK-3b kinase activity
through site-specific phosphorylation at Ser9 [22]. Suppression of
Akt which leads to de-phosphorylation and activation of GSK-3b
cause phosphorylation of cyclin D1 at Thr286 and the subsequent
proteasomal degradation [23]. Cyclin D1 has been shown to be
overexpressed in many cancers including breast, head and neck,
esophagus and prostate [24,25]. In this study, we found that BP is
capable of inhibiting Akt activation by reducing Ser473 phos-
phorylation, and restores GSK-3b kinase activity by reducing Ser9
phosphorylation in prostate cancer cells. These data suggest that
BP suppresses prostate cancer cells proliferation via cell cycle
arrest by regulating the cyclin/CDK/CKI cell cycle regulatory
protein and targeting the Akt-GSK-3b-Cyclin D1 signaling axis.
To investigate the underlying molecular mechanisms of BP-
induced prostate cancer cells death, we examined the BP-induced
changes in gene expression in human prostate cancer cells using an
oligodeoxynucleotide-based microarray screening assay. Several
genes showing greater than two-fold increase in expression at 24 h
of BP treatment were identified (Table 1). GADD153/CHOP
showed dramatically 11.89 folds increase of expression after BP
treatment. GADD153/CHOP is a gene of interest as it is involved in
ERstress-mediated apoptoticpathway. Activation of the UPR plays a
protective role to cells under ER stress [26]. However, prolonged
activation of UPR by excessive ER stress can convert its role to
cytotoxic by activation of multiple apoptotic pathways in mammalian
cells [27]. The ER stress transducer proteins ATF6, IRE1-a and
PERK constitute the core stress regulator of the UPR, and transduce
signals from the ER to the cytoplasm and nucleus after ER stress [28–
30]. In our study, BP induced only IRE1-a activation but not ATF6
or p-eIF2a in prostate cancer cells. Increasing and sustaining
expression of IRE1-a and its downstream target GADD153/CHOP
after BP treatment were observed in time- and dose- dependent
manner. One of the mechanisms implicated in GADD153/CHOP-
mediated apoptosis is oxidative stress [31]. Oxidation of the ER
lumen is induced by the GADD153/CHOP downstream target
ERO1-La.E R O 1 - L a has been speculated to hyperoxidize the ER
lumen, and causes cytotoxic reactive oxygen species (ROS)
production that leads to cell death. Another mechanism was
associated with the role of Bax in GADD153/CHOP induced
apoptosis. In ER-stress-induced cardiomyocyte aopotosis, Bax
increase with ER stress in a GADD153/CHOP-dependent manner
[32]. Bax and Bak also modulate UPR by a direct interaction with
IRE1-a,andareimportantlinkbetweenIRE1-amediatedER-stress-
induced apoptosis.Our results showed that transfection of siRNAs for
IRE1-a or GADD153/CHOP suppressed BP-induced cell death.
Taken together, these findings suggest that BP may modulate ER
stress-mediated apoptosis of human prostate cancer cells through
activation of IRE1-a-GADD153/CHOP signaling pathway.
Treatment with BP triggered increased expression of Fas, which
led to the activation of caspase-8 and -3 in malignant brain tumor
in our previous study [5]. Fas overexpression also increased at 3 h
after BP treatment. Thus, BP-induced apoptosis of human prostate
cancer cells might be mediated, at least partially, through death
receptor apoptosis pathway.
Furthermore, activation of MAPKs has been implicated in the
regulation of gene expression in the ER stress signaling cascade
and is involved in many aspects of the control of cellular
proliferation and apoptosis. The JNK pathway has also been
Table 1. Gene expressed differently in BP-treated LNCaP cells.
Change* (,fold)
Functional Classification and Accession No Representative Gene Name 24 h 3 h
Signal transduction
NM 004864 NSAID-activated gene 1 (NAG-1) 5.66 2.92
Transcription factor
NM 001924 Growth arrest and DNA-damage-inducible, alpha (GADD45A) 4.05 3.43
ER stress
NM 001195053 DNA-damage-inducible transcript 3 (DDIT3/GADD153/CHOP) 11.89 7.26
NM 001433 Endoplasmic reticulum to nucleus signaling 1 (ERN1/IRE1) 2.51 N/A
NM 007348 Activating transcription factor 6 (ATF6) 2.31 N/A
Cell cycle
NM 000389 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 6.29 N/A
Apoptosis
NM 001225 Caspase 4 2.54 N/A
NM 006437 Poly (ADP-ribose) polymerase family, member 4 (PARP4) 3.414 N/A
NM 000043.4 Fas (TNF-receptor superfamily, member 6, CD95/APO-1) 2.191 N/A
*Genes list above are those that increased by .2-fold after BP treatment. N/A, Not Applicable.
doi:10.1371/journal.pone.0033742.t001
n-butylidenephthalide Induces ER Stress in PCa
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33742shown to be a positive regulator of ER stress induced apoptosis
[33]. In our study, phosphorylation of JNK was observed after BP
treatment. Inhibition of JNK expression by siRNA led to the
down-regulation of IRE1-a and GADD153/CHOP, and partially
rescued BP-induced cell death. ER stress-activated IRE1-a binds
the adaptor protein tumor necrosis factor receptor-associated
factor2 (TRAF2), an E3 ubiquitin ligase, which in turn activates
the apoptosis signal-regulating kinase 1 (ASK1; also known as
MAP3K5), subsequently causes JNK activation. These findings
implicate the notion that BP-induced ER stress-mediate cell death
via the cooperation of the JNK pathway.
Tumor necrosis factor related apoptosis inducing ligand (TRAIL)
is a death receptor ligand that can preferentially initiate apoptosis in
various tumor cells. Recently, TRAIL-based therapeutics, including
TRAIL gene therapy, recombinant TRAIL, and TRAIL-receptor-
agonistic antibodies have entering clinical trials [34–37]. However,
similar to many other cancers, prostate cancer develop resistance to
TRAIL [38,39]. Therefore, seeking for TRAIL sensitizers capable
of overcoming TRAIL resistance in cancer cells are valuable.
LNCaP are known to be resistant to TRAIL-induced apoptosis
associated with the absence of PTEN that promote constitutive
activation of the AKT/PI3K pathway. Since BP efficiently
diminished the Akt activity by reducing the level of phospho-Akt
Ser473, which makes BP a candidate of TRAIL sensitizer.
In conclusion, our study demonstrated that BP 1) causes prostate
cancer cell cycle arrest at G0/G1 phase by targeting the Akt-GSK-
Figure 4. BP induces ER stress-related genes expression in prostate cancer cells. Western blot analysis of BiP, calnexin, PDI, ATF6, phospho-
eIF2a (Ser51), IRE1-a, GADD153/CHOP, phosphor-ASK1 (Thr845), ASK1 and Fas were performed in LNCaP cells (A) and PC-3 cells (B). b-actin was used
as an internal control. Western blot analysis of BiP, IRE1-a, GADD153/CHOP and Ero1-La were performed in LNCaP cells (C) and PC-3 cells (D). b-actin
was used as an internal control.
doi:10.1371/journal.pone.0033742.g004
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JNK-mediated UPR; 3) triggers apoptosis of human prostate cancer
cells through multiple apoptotic pathways in vitro and in vivo (Fig. 9).
Materials and Methods
Cell cultures and Reagents
The human prostate cell lines LNCaP and PC-3 were purchased
from ATCC (American Type Culture Collection, Manassas, VA),
and cultured in RPMI 1640 medium with 10% heat-inactivated
fetal bovine serum, 100 U/ml penicillin and 100 U/ml streptomy-
cin, 1% sodium pyruvate, 2 mM L-glutamine (all of these reagents
are from Invitrogen, Carlsbad, CA) at 37uC in a humidified
atmosphere with 5% CO2. n-Butylidenephthalide (Lancaster
Synthesis Ltd., Newgate, Morecambe, UK) was dissolved in
dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO, USA) to a
concentration of 100 mg/ml and stored at 220uC as a master stock
solution. The RNA isolation kit was purchased from QIAGEN
(Valencia,CA). Dimethylsulfoxide(DMSO),3-(4,5-dimethyl thizol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT), paclitaxel, and
horseradish peroxidase-conjugated secondary antibodies were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Figure 5. Nuclear translocation of GADD153/CHOP after BP treatment in human prostate cancer cells. (A) LNCaP cells and (B) PC-3 cells
were treated with 0.2% DMSO (control) or 70 mg/ml BP for 12 h, fixed and stained with anti-GADD153/CHOP. FITC-labeled secondary antibody was
used (green fluorescence) Nuclei were stained with DAPI (blue fluorescence). Images were captured by a confocal laser microscope.
doi:10.1371/journal.pone.0033742.g005
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33742Polyvinyldenefluoride (PVDF) membranes, BSA protein assay kit
and western blot chemiluminescence reagent were purchased from
Amersham Biosciences (Arlington Heights, IL).
Microarray analysis
A total of 100 ng of total RNA was amplified according to
Affymetrix’s small sample protocol (GeneChip Eukaryotic Small
Sample Target Labeling Technical Note), and 15 mg of cRNA was
then hybridized to Human gene 1.0 ST array (Affymetrix) and
scanned. Image files were processed using MAS5.0 to produce
Affymetrix expression data files. Data were then imported into
GeneSpring (7.2; Silicon Genetics) and per chip normalization
performed, using the 50th percentile of all measurements in that
sample. All data is MIAME compliant and that the raw data has
been deposited in a MIAME compliant database (accession
number: GSE33883, http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?token=nropzqwssewqylo&acc=GSE33883)
Western blot analysis
LNCaP cells were lysed on ice with 200 ml lysis buffer (50 mM
Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM MgCl2, 0.5% Nonidet P-40,
1 mM phenylmethylsulfonyl fluoridefor, 1 mg/ml pepstatin, and
50 mg/ml leupeptin) and centrifuged at 13,0006ga t4 uCf o r5m i n .
The protein concentrations in the supernatants were quantified using
a BSA Protein Assay Kit. Electrophoresis was performed on a
NuPAGE Bis-Tris Electrophoresis System using 20 mgo fr e d u c e d
protein extract per lane. Resolved proteins were transferred to PVDF
membranes, blocked with 5% non-fat milk for 1 h at room
temperature, finally probed with appropriately dilution of primary
antibodies at 4uC overnight: GADD153/CHOP, Bip, calnexin, PDI,
IRE1-a, Ero1-La, cyclin D1, CDk2, phospho-Rb (Ser807/811),
phospho-Akt (Ser473), Akt, phospho-GSK3b (Ser9), GSK3b,
phosphor-ASK1 (Thr845), Fas, cleaved caspase-3 (Asp175), cas-
pase-8 (1C12), Bax, MAPK family antibody, phosphor-MAPK
family antibody, p16, p21 and p27 (Cell Signaling Technology, Inc.,
Danvers, MA). ATF6 (Abcam, Inc., Cambridge, MA), and ASK1
(GeneTex, Inc., San Antonio, TX). After the PVDF membrane was
washed three times with TBS/0.2% Tween 20 at room temperature,
it was incubated with appropriate secondary antibody labeled with
horseradish peroxidase (goat anti-mouse or anti-rabbit, 1:10000,
Sigma Chemical, St. Louis, MO) for 1 h at room temperature. All
resolved proteins bands were detected using Western Lightning
TM
Chemiluminescence Reagent Plus(Amersham Biosciences,Arlington
Heights, IL) and quantified with densitometers.
Growth inhibition assay
The viability of cells after treatment with various chemicals was
evaluated using MTT assay preformed in triplicate. Briefly, the
LNCaP cells (2610
5/well) and PC-3 cells (2610
5/well) were
incubated in 6-well plates containing 2 ml of serum-containing
medium. Cells were allowed to adhere for 18–24 h, and were
washed withphosphate-bufferedsaline (PBS).Solutions werealways
freshly prepared by dissolving 0.2% DMSO (control) or drugs in
serum-containing culture medium before their addition to LNCaP
cells. The drug-containingmediumwasremovedafter treatment for
indicated time, cells were washed with PBS, and culture medium
containing 300 mg/ml MTT was added for 1 h at 37uC. After the
MTT medium was removed, 2 ml of DMSO were added to each
well. Absorbance at 570 nm was detected by a PowerWave X
Microplate ELISA Reader (Bio-Tek Instruments, Winooski, VT).
The absorbance for DMSO-treated cells was considered as 100%.
Cell cycle analysis
The cell cycle was determined by flow cytometry using DNA
staining dye to reveal the total amount of DNA. Approximately
5610
5 LNCaP cells were incubated with 70 mg/ml BP for the
indicated time. Cells were harvested with trypsin/EDTA,
collected, washed with PBS, fixed with cold 100% ethanol
overnight, and then stained with a solution containing 20 mg/ml
PI, 0.2 mg/ml RNase A, and 0.1% Triton X-100 for 30 min in
the dark. The cells were then analyzed with FACScan flow
cytometer (equipped with a 488-nm argon laser) to measure the
DNA content. The data were obtained and analyzed with
CellQuest 3.0.1 (Becton Dickinson, Franklin Lakes, NJ) and
ModFitLT V2.0 software.
Transfection with siRNA
GADD153/CHOP and IRE1-a siRNA were designed by
siGENOME ON-TARGET plus SMARTpool siRNA purchased
from Dhamarcon RNAi Technologies. GADD153/CHOP (DDIT3)
target sequences are: GGUAUGAGGACCUGCAAGA, CACCAA
GCAUGAACAAUUG, GGAAACAGAGUGGUCAUUC, CAG-
CUGAGUCAUUGCCUUU. IRE1-a (ERN1) targetsequences are:
CUACCCAAACAUCGGGAAA, CUCCAGAGAUGCUGAGC
GA, AUAAUGAAGGCCUGACGAA, GUCCAGCUGUUGCG
AGAAU. Non-targeting control sequences were not provided. JNK
1/2 siRNA (1, # 6232, 2, # 6233) was purchased from Cell
Signaling Technology, Inc. (Danvers, MA) and sequences were not
provided. LNCaP cells at 50 to 60% confluence were transfect with
siRNA (10–50 nM) using the RNAifect Transfection Regaent
(QIAGEN) according to the manufacturer’s protocol. Cells were
cultured for 48 h, and then treated with BP or vehicle for an
additional 24 or 48 h. Protein were then isolated for western blotting,
or cells were collected for the MTT assay.
TUNEL assay
LNCaP and PC-3 cells were cultured in the presence or absence
of BP (70 mg/ml) for 48 h and then examined for apoptosis with
TUNEL assay (In Situ Cell Death Detection kit, Roche).
Immunocytochemistry
LNCaP cells cultured on glass slides were treated with 70 mg/ml
BP for 12 h prior to fixation with cold 4% para-formaldehyde. The
fixed cells were washed twice in PBS, and incubated in cold
permeabilization solution (0.3% Triton X-100+0.1% sodium
citrate). After endogenous peroxidase activity was inactivated with
Figure 6. BP induces GADD153 and IRE1-a dependent cell death. (A) LNCaP cells were transfected with scramble siRNA (
#), 20, or 40 nM
GADD153 siRNA, respectively, for 48 h using the RNAifect transfection reagent. After 24 h treatment with 70 mg/ml BP, western blot analysis was
performed for GADD153. (B) BP-induced anti-proliferative activity was measured with MTT assay in LNCaP cells transfected with scramble siRNA (
#)o r
20 nM GADD153 siRNA for 48 h and then treated with 70 mg/ml BP for 24 h. Data are expressed as means 6 S.D. from three independent
experiments. ***, P,0.001. (C) LNCaP cells were transfected with scramble siRNA (
#), 20, or 50 nM IRE1-a siRNA, respectively, for 48 h using the
RNAifect transfection reagent. After 24 h of treatment with 70 mg/ml BP, western blot analysis was performed for IRE1-a and GADD153, respectively.
b-actin was used as an internal control. (D) BP-induced anti-proliferative activity was measured with MTT assay in LNCaP cells transfected with
scramble siRNA (
#), 20, or 50 nM IRE1-a siRNA, respectively, for 48 h and then treated with 70 mg/ml BP for 24 h. Data are expressed as means 6 S.D.
from three independent experiments. ***, P,0.001 versus vehicle.
doi:10.1371/journal.pone.0033742.g006
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anti-GADD153 at 4uC overnight. The cells were washed with PBS
three times and then incubated with FITC-conjugated secondary
antibody 1 h at room temperature. The cells werethen washed with
PBSthree timesand stainedwith 300 nM DAPI for 10 min. Images
were obtained with the confocal microscope (Carl Zeiss, Oberko-
chen, Germany).
Animal studies
Ethics Statement: The animal use protocol listed below has
been reviewed and approved by Institutional Animal Care and
Use Committee (IACUC), Buddhist Tzu Chi General Hospital,
approval No: 95-51.
To examine the anti-tumor effects of BP in vivo, the LNCaP
human prostate cancer cells were used in male NOD-SCID mice
Figure 7. BP-induced ER stress and cell death are JNK1/2 dependent. (A) LNCaP cells and (B) PC-3 cells were treated with 70 mg/ml BP for the
indicated times. Phospho-ERK1/2, total ERK1/2, phospho-JNK1/2, total JNK1/2, phospho-p38, and total p38 were detected by western blotting
respectively. (C) LNCaP cells were transfected with scramble (
#) or 20 nM JNK1/2 siRNA for 48 h using the RNAifect transfection reagent. After
treatment with 70 mg/ml BP for 24 h, western blot analysis was performed for phospho-JNK1/2, total JNK1/2, IRE1-a and GADD153. b-actin was used
as an internal control. (D) BP-induced anti-proliferative activity was measured with MTT assay in LNCaP cells transfected with scramble (
#) or JNK1/2
siRNA for 48 h and then treated with 70 mg/ml BP for 24 h. Data was expressed as means 6 S.D. from three independent experiments. ***, P,0.001
versus vehicle.
doi:10.1371/journal.pone.0033742.g007
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5
LNCaP cells into the dorsal subcutaneous tissue. When the tumor reached 100–250 mm
3, LNCaP tumor-bearing mice were administrated s.c. with
vehicle control (&) or 500 mg/kg BP (N) on days 0–4 for 5 days. The relative tumor volumes of control and the BP-treated groups were shown as
means 6 S.D. of tumor volume at each time point. (B) Tumors of control and therapeutic groups were removed and weighted on day 18. Average
tumor weight from the BP-treated group was 56% smaller than control group. Data was expressed as means 6 S.D. of tumor weight of the control
and the BP-treated groups. **, P,0.01. (C, D) Tumor tissue sections with HE staining of control (C) and therapeutic groups (D).GADD153 expressions
were immunohistochemically identified in the control (E) and the BP-treated group (F). The GADD153-positive cells were stained brown. Expression of
GADD153 and active form caspase-3 in the LNCaP xenograft tumor tissue were upregulated after BP administration as compared to control group by
western blotting analysis (G).
doi:10.1371/journal.pone.0033742.g008
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National Laboratory Animal Center (Taipei, Taiwan). All
procedures were performed in compliance with the standard
operating procedures of the Tzu Chi University Laboratory
Animal Center (Hualien, Taiwan). All experiments were carried
out using 6–8 week old mice weighing 18–22 g. The animals were
subcutaneous implanted with 5610
5 LNCaP cells into the back of
mice. When the tumor reached 80–150 mm
3 in volume, animals
were divided randomly into control and test groups consisting of
six mice per group (day 0). Subcutaneous injection of either corn
oil (control group), or 500 mg/kg of BP (treatment groups) was
given for five successive days. BP was dissolved in a vehicle of 20%
Tween 80 in normal saline (v/v). The injection sites were .1.5 cm
from the tumors. Mice were weighed three times a week up to day
18–21. The tumor volume was also determined by measurement
of the length (L) and width (W) of the tumor. The tumor volume at
day n (TVn) was calculated as TV (mm
3)=(L 6W
2)/2. The
relative tumor volume at day n (RTVn) versus day 0 was expressed
according to the following formula: RTVn=TVn/TV0. Tumor
regression (T/C (%)) in treated versus control mice was calculated
using: T/C (%)=(mean RTV of treated group)/(mean RTV of
control group)6100. Xenograft tumors as well as other vital
organs of treated and control mice were harvested and fixed in 4%
formalin, embedded in paraffin, and cut in 4-mm sections for
histological analysis.
Statistical analysis
All data are shown as mean 6 S.D. Statistical differences were
analyzed using the Student’s t-test for normally distributed values
and by nonparametric Mann–Whitney U-test for values with a
non-normal distribution. Values of P,0.05 were considered
significant.
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